2026-04-17T11:30:54Zhttps://recercat.cat/oai/request

oai:recercat.cat:10256/205092024-06-18T12:41:29Zcom_2072_452955com_2072_2054col_2072_453079

Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report Anna Carbó-Bagué Roser Fort-Culillas Helena Pla-Juher Rubió Casadevall, Jordi Anèmia hemolítica Hemolytic anemia Autoimmune haemolytic anaemia (AIHA) is a rare immune-related adverse event and appears to be more common with anti-PD1/PDL1 than anti-CTLA4. Little is known about the safety of re-treating with anti-PD1/PDL1 or changing to anti-CTLA4. We present a case of grade 4 AIHA due to nivolumab (PD1-inhibitor) treatment in a patient with melanoma for adjuvant setting after surgery and the safeness of subsequent treatment with ipilimumab (anti-CTLA4). After the remission of AIHA with steroids, ipilimumab was started with the rationale of its different mechanism of action. Fortunately, AIHA did not recur. The mechanism by which checkpoint inhibitors cause AIHA is likely by augmenting or redirecting immune surveillance, especially by activating pre-existing red blood cell autoantibodies, but further studies must be done. To our knowledge, this is the first case published in the literature with the change of immunotherapy treatment to anti-CTLA4 2021-09-14 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion peer-reviewed http://hdl.handle.net/10256/20509 http://hdl.handle.net/10256/20509 eng info:eu-repo/semantics/altIdentifier/issn/1662-6575 Reconeixement-NoComercial 4.0 Internacional http://creativecommons.org/licenses/by-nc/4.0 info:eu-repo/semantics/openAccess application/pdf Karger Publishers Case Reports in Oncology, 2021, vol. 14, núm. 3 Articles publicats (IdIBGi) Anna Carbó-Bagué Roser Fort-Culillas Helena Pla-Juher Rubió Casadevall, Jordi 2021 Nivolumab-Induced Autoimmune Haemolytic Anaemia and Safety of Subsequent Use of Ipilimumab: A Case Report Case Reports in Oncology 14 3